A carregar...
Emerging novel therapies in the treatment of castrate-resistant prostate cancer
The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review takes...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Canadian Medical Association
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3104424/ https://ncbi.nlm.nih.gov/pubmed/21470540 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.10160 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|